Actuate TherapeuticsNASDAQ: ACTU

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$153.08 M
-12%vs. 3y high
50%vs. sector
-vs. 3y high
-vs. sector
0%vs. 3y high
10%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 13 Sep 2024 13:30:00 GMT
$8.01+$0.06(+0.75%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

Included in screeners

No data

ACTU Latest News

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
globenewswire.com09 September 2024 Sentiment: POSITIVE

CHICAGO and FORT WORTH, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- – Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), provided an update on its Phase 1/2 trial of elraglusib in relapsed/refractory Ewing Sarcoma (r/r EWS).

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline
seekingalpha.com17 August 2024 Sentiment: NEUTRAL

This week was another slow week for pricings, with two companies making their public debut, along with three SPACs. On the filing side, offshore-focused drilling equipment and aftermarket service provider, HMH Holding, filed to raise $100 million. Three IPOs are currently scheduled to list in the week ahead, all based in the Asia Pacific region. One SPAC is also expected to price.

What type of business is Actuate Therapeutics?

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

What sector is Actuate Therapeutics in?

Actuate Therapeutics is in the Healthcare sector

What industry is Actuate Therapeutics in?

Actuate Therapeutics is in the Biotechnology industry

What country is Actuate Therapeutics from?

Actuate Therapeutics is headquartered in United States

What is Actuate Therapeutics website?

https://actuatetherapeutics.com

Is Actuate Therapeutics in the S&P 500?

No, Actuate Therapeutics is not included in the S&P 500 index

Is Actuate Therapeutics in the NASDAQ 100?

No, Actuate Therapeutics is not included in the NASDAQ 100 index

Is Actuate Therapeutics in the Dow Jones?

No, Actuate Therapeutics is not included in the Dow Jones index

When was Actuate Therapeutics the previous earnings report?

No data

When does Actuate Therapeutics earnings report?

Next earnings report date is not announced yet